Advertisement

 

 

Serum nesfatin-1 levels in patients with different glucose tolerance levels.

Serum nesfatin-1 levels in patients with different glucose tolerance levels.
Author Information (click to view)

Algul S, Ozkan Y, Ozcelik O,


Algul S, Ozkan Y, Ozcelik O, (click to view)

Algul S, Ozkan Y, Ozcelik O,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Physiological research 2016 08 1965(6) 979-985
Abstract

The aim of this study was to compare the levels of nesfatin-1 in healthy subjects with those in prediabetic and diabetic patients who have different glucose tolerance levels. Overall, 100 subjects were divided into 5 groups healthy control (C), impaired fasting glycemia (IFG), impaired glucose tolerance (IGT), metabolic syndrome (MS) and type 2 diabetes mellitus, (Type 2 DM). Glycated hemoglobin (HbA1c) assessed the glycemic control. Homeostasis model assessment of insulin resistance (HOMA-IR) was determined using computer analyses. Nesfatin-1 levels were measured using ELISA method. IFG and IGT (prediabetic groups) from MS and Type 2 DM (diabetic groups) differed significantly in HOMA-IR. The nesfatin-1 levels were lower, although not statistically significant, in IFG (0.937+/-0.03 ng/ml, p=0.07) and IGT (1.039+/-0.06 ng/ml, p=0.5) groups compared to healthy subjects (1.094+/-0.07 ng/ml). However, the nesfatin-1 levels were lower in patients with Type 2 DM (0.867+/-0.02 ng/ml, p=0.007) and MS (0.885+/-0.01 ng/ml, p=0.01) compared to healthy subjects. Nesfatin-1 levels were significantly lower in diabetic patients compared to healthy subjects. This study supports the role of insulin resistance in decreased nesfatin-1 levels in patients with Type 2 DM and MS.

Submit a Comment

Your email address will not be published. Required fields are marked *

fifteen + 17 =

[ HIDE/SHOW ]